Cagrilintide: Dosing Protocols

Dosing Disclaimer#

Cagrilintide is an investigational compound that has not received regulatory approval as a standalone product. The dosing information below is derived from published clinical trial protocols and peer-reviewed publications. This information is for educational and research purposes only and does not constitute medical advice. CagriSema (the combination with semaglutide) is in advanced clinical development but is also not yet approved.

Clinical Trial Dosing#

Phase 2 Monotherapy Doses#

The phase 2 dose-finding study (Lau et al., The Lancet, 2021; PMID: 34798060) evaluated five dose levels of cagrilintide as monotherapy: 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg, all administered once weekly by subcutaneous injection. This dose range was selected based on preclinical pharmacokinetic and pharmacodynamic modeling that predicted meaningful amylin receptor engagement across these levels.

The results demonstrated a clear dose-response relationship for weight loss. At 26 weeks, the mean percentage body weight change from baseline was approximately 3.0% for placebo, 4.0% for 0.3 mg, 5.3% for 0.6 mg, 7.0% for 1.2 mg, 9.0% for 2.4 mg, and 10.8% for 4.5 mg. The weight loss curve had not fully plateaued at 26 weeks for the higher dose groups, suggesting that longer treatment duration would yield additional weight loss.

The dose-response relationship for adverse events was also apparent, with higher doses producing more frequent gastrointestinal symptoms, particularly nausea. The incidence of nausea was approximately 20 to 30% for the 2.4 mg and 4.5 mg dose groups during the titration phase, declining substantially after the first 8 to 12 weeks of treatment.

CagriSema Combination Dosing#

In the phase 1b combination study (Enebo et al., PMID: 33894838), cagrilintide was administered at 0.16 to 4.5 mg weekly in combination with semaglutide 2.4 mg weekly. Both peptides were administered as separate subcutaneous injections in the clinical trial setting. The CagriSema 2.4 mg plus 2.4 mg combination (the higher dose) produced the most robust weight loss results and was selected as the lead combination for phase 3 development.

In the phase 3 REDEFINE program, CagriSema is administered using a combination prefilled pen device that delivers both cagrilintide and semaglutide in a single injection. This combination device simplifies the injection burden compared to two separate injections and improves treatment adherence.

Dose Titration#

Importance of Gradual Titration#

Dose titration is a critical aspect of cagrilintide administration. Both the amylin and GLP-1 components of CagriSema require gradual dose escalation to minimize the gastrointestinal side effects (primarily nausea, vomiting, and diarrhea) that are the most common reason for treatment discontinuation.

The titration approach for cagrilintide follows the same principle used with semaglutide: treatment is initiated at a low dose and increased in steps at 4-week intervals until the target maintenance dose is reached. This gradual approach allows the gastrointestinal tract and central appetite-regulatory circuits to adapt to the pharmacological effects, reducing the severity of initial side effects.

Typical Titration Schedule#

Based on the clinical trial protocols and the approach used for other long-acting peptide therapies, the typical cagrilintide titration schedule involves starting at 0.25 mg weekly for the first 4 weeks, then escalating through intermediate doses (0.5 mg, 1.0 mg, 1.7 mg) at 4-week intervals, reaching the maintenance dose of 2.4 mg weekly after approximately 16 to 20 weeks of titration.

For CagriSema, both components are titrated simultaneously, with each component following its own dose-escalation schedule. The semaglutide component follows the established titration from the STEP program (0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg), while the cagrilintide component follows a parallel titration schedule.

Administration Technique#

Injection Method#

Cagrilintide is administered by subcutaneous injection using a prefilled pen device (in the clinical trial formulation) or potentially via a syringe in research settings. The injection technique follows standard subcutaneous administration practices. The prefilled pen is designed for patient self-administration without requiring specialized training.

The injection should be administered into the subcutaneous tissue of the abdomen (at least 5 centimeters from the navel), the front of the thigh, or the upper arm. Injection sites should be rotated between administrations to minimize the risk of injection site reactions or lipodystrophy.

Timing Considerations#

Unlike short-acting amylin analogs (pramlintide) that must be injected before meals, cagrilintide can be administered at any time of day regardless of meals, due to its long half-life and sustained pharmacological action. The once-weekly injection can be given on the same day each week, with flexibility to change the day of injection if needed (as long as there are at least 3 days between injections).

If a dose is missed, it should be administered as soon as possible within 3 days of the scheduled dose. If more than 3 days have elapsed, the missed dose should be skipped and the next dose taken on the regularly scheduled day.

Formulation and Preparation#

Cagrilintide in the clinical development program is supplied as a clear, colorless to slightly yellow, isotonic solution in a prefilled, disposable pen injector. No reconstitution or dilution is required, which eliminates a common source of dosing errors with lyophilized peptide products. The pen device includes a dose counter and dose-limiting mechanism to prevent accidental overdose.

Each pen contains a fixed volume of solution at a specific concentration, with different pen strengths available for the titration and maintenance phases. The needle used for injection is a standard disposable pen needle (typically 30 to 32 gauge, 4 to 8 mm in length).

Storage and Handling#

Unused prefilled pens should be stored refrigerated at 2 to 8 degrees Celsius, protected from light. The pens should not be frozen. Once an in-use pen has been removed from refrigeration, it may be stored at room temperature (not exceeding 30 degrees Celsius) for up to 6 weeks. After 6 weeks at room temperature or after the expiration date printed on the pen (whichever comes first), the pen should be discarded.

The solution should be visually inspected before each injection. If the solution appears cloudy, discolored, or contains particulate matter, the pen should not be used. The pen cap should be replaced after each use to protect the solution from light exposure.

Dose Adjustment Considerations#

In clinical trials, dose adjustment or temporary dose reduction has been employed for participants experiencing significant gastrointestinal adverse events. If nausea, vomiting, or diarrhea is severe or persistent, a temporary reduction to the previous dose step for 4 weeks may be considered before re-attempting escalation. In some cases, a slower titration schedule (with 8-week intervals between dose increases instead of 4 weeks) may improve tolerability.

No dose adjustment is required for mild to moderate renal or hepatic impairment based on pharmacokinetic data from the clinical program. Cagrilintide has not been studied in severe renal or hepatic impairment.

Related Reading#

• Cagrilintide overview and research guide
• Cagrilintide side effects profile
• Cagrilintide research evidence